195 related articles for article (PubMed ID: 8711090)
1. FDA shortened drug approval time in 1995.
Public Health Rep; 1996; 111(4):290. PubMed ID: 8711090
[No Abstract] [Full Text] [Related]
2. Significant FDA approvals in 2000.
McGinnis TJ
Am Fam Physician; 2001 May; 63(10):2061-4. PubMed ID: 11388719
[No Abstract] [Full Text] [Related]
3. Making medical progress. A look at FDA approvals in 2000.
FDA Consum; 2001; 35(2):7-8. PubMed ID: 11444251
[No Abstract] [Full Text] [Related]
4. HIV drugs. FDA new drug approval rate lowest in 10 years.
AIDS Policy Law; 2007 Jan; 22(2):5. PubMed ID: 17323437
[No Abstract] [Full Text] [Related]
5. Muddied messages about FDA.
Miller HI
Nat Biotechnol; 2003 Jul; 21(7):732-3. PubMed ID: 12833084
[No Abstract] [Full Text] [Related]
6. FDA new drug approvals in 2003.
Wynn RL
Gen Dent; 2004; 52(4):294-8, 300. PubMed ID: 15366292
[No Abstract] [Full Text] [Related]
7. Mid-year at the FDA highlights permanent problem.
Howard K
Nat Rev Drug Discov; 2004 Aug; 3(8):637. PubMed ID: 15317145
[No Abstract] [Full Text] [Related]
8. FDA reform in Congress: interview with Peter Barton Hutt. Food and Drug Administration. Interview by John S. James.
Hutt PB
AIDS Treat News; 1996 Apr; (no 245):4-5. PubMed ID: 11363623
[TBL] [Abstract][Full Text] [Related]
9. Communicating with the FDA: the "third rail" of a new model for drug development.
Stanski DR; Orloff JJ
J Clin Pharmacol; 2008 Feb; 48(2):144-5. PubMed ID: 18199890
[No Abstract] [Full Text] [Related]
10. FDA clears 25 new drugs for marketing in 1993.
Am J Hosp Pharm; 1994 Apr; 51(7):865, 869. PubMed ID: 8017431
[No Abstract] [Full Text] [Related]
11. Vouchers for FDA priority reviews.
Spatz ID
Health Aff (Millwood); 2006; 25(4):1184; author reply 1184-5. PubMed ID: 16835203
[No Abstract] [Full Text] [Related]
12. 2007 FDA drug approvals: a year of flux.
Hughes B
Nat Rev Drug Discov; 2008 Feb; 7(2):107-9. PubMed ID: 18246607
[No Abstract] [Full Text] [Related]
13. 2011 FDA drug approvals.
Mullard A
Nat Rev Drug Discov; 2012 Feb; 11(2):91-4. PubMed ID: 22293555
[No Abstract] [Full Text] [Related]
14. Balancing US patent and FDA approval processes: strategically optimizing market exclusivity.
Fernandez DS; Huie JT
Drug Discov Today; 2004 Jun; 9(12):509-12. PubMed ID: 15183155
[No Abstract] [Full Text] [Related]
15. The drive to reform the FDA gains momentum.
Gatty B
Hosp Formul; 1995 Mar; 30(3):178, 177. PubMed ID: 10141250
[No Abstract] [Full Text] [Related]
16. Key factors in the rising cost of new drug discovery and development.
Dickson M; Gagnon JP
Nat Rev Drug Discov; 2004 May; 3(5):417-29. PubMed ID: 15136789
[No Abstract] [Full Text] [Related]
17. The FDA speeds medical treatments for serious diseases.
Rados C
FDA Consum; 2006; 40(2):9-12. PubMed ID: 16671194
[No Abstract] [Full Text] [Related]
18. FDA evaluates accelerated approval process. Food and Drug Administration.
Common Factor; 1995 Apr; (no 10):18. PubMed ID: 11362343
[TBL] [Abstract][Full Text] [Related]
19. Medical devices; 30-day notices and 135-day PMA supplement review--FDA. Direct final rule; withdrawal.
Fed Regist; 1998 Aug; 63(154):42699. PubMed ID: 10182563
[TBL] [Abstract][Full Text] [Related]
20. FDA advisory panel voices persistent safety concerns.
Finkelstein JB
J Natl Cancer Inst; 2006 Apr; 98(7):439. PubMed ID: 16595778
[No Abstract] [Full Text] [Related]
[Next] [New Search]
